Loading
Life sciences · Journal article
Pharmacia · August 10, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes evidence on vitamin D, berberine, and chromium for insulin resistance, identifying plausible mechanisms but finding clinical efficacy heterogeneous and dependent on population and study factors. The authors recommend these agents only as adjuncts to lifestyle change and standard therapy in selected high-risk individuals, with a call for rigorous future trials.
Narrative review. Studies addressing vitamin D, berberine, or chromium in the context of insulin resistance and related metabolic disorders. Intervention: Vitamin D, berberine, and chromium as nutritional supplements.
Three supplements (vitamin D, berberine, chromium) influence insulin resistance through distinct mechanisms: insulin signaling, inflammation, oxidative stress, and glucose metabolism Clinical findings are heterogeneous and appear dependent on baseline nutritional status, metabolic phenotype, supplement formulation, and study design Current evidence supports use only as adjuncts to lifestyle modification and evidence-based therapy in selected individuals with increased metabolic risk
No specification of which populations or metabolic phenotypes showed benefit versus harm
Clinicians should not prescribe vitamin D, berberine, or chromium as monotherapy for insulin resistance. These agents may be considered as complementary interventions in selected high-risk patients alongside standard lifestyle and pharmacological management, but lack sufficient evidence to recommend routine use pending future trials.
A narrative review synthesizing mechanistic and clinical evidence on three supplements for insulin resistance, concluding they should be adjuncts to lifestyle and standard therapy in selected patients, pending future RCTs.
As stated by the source record.
Clinicians should not prescribe vitamin D, berberine, or chromium as monotherapy for insulin resistance. These agents may be considered as complementary interventions in selected high-risk patients alongside standard lifestyle and pharmacological management, but lack sufficient evidence to recommend routine use pending future trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Insulin resistance is a central mechanism underlying metabolic syndrome, type 2 diabetes mellitus, obesity, and related cardiometabolic disorders. This narrative review critically evaluates the current evidence regarding vitamin D, berberine, and chromium as complementary nutritional interventions for insulin resistance. A structured literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar for English-language publications published between 2010 and March 2026, with landmark earlier studies included where appropriate. Mechanistic, preclinical, observational, and clinical evidence was synthesized narratively. The reviewed supplements influence insulin resistance through distinct mechanisms involving insulin signaling, inflammation, oxidative stress, and glucose metabolism. However, clinical findings remain heterogeneous and appear to depend on baseline nutritional status, metabolic phenotype, supplement formulation, and study design. Current evidence supports their use only as adjuncts to lifestyle modification and evidence-based therapy in selected individuals with increased metabolic risk. Future well-designed randomized controlled trials are required to define their long-term efficacy, safety, and role in personalized metabolic management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.